[发明专利]氘化氨基缩水甘油基化合物无效
申请号: | 200780028058.5 | 申请日: | 2007-05-25 |
公开(公告)号: | CN101528669A | 公开(公告)日: | 2009-09-09 |
发明(设计)人: | T·G·甘特;S·萨沙 | 申请(专利权)人: | 奥斯拜客斯制药有限公司 |
主分类号: | C07C217/30 | 分类号: | C07C217/30;C07C217/34;C07B59/00;A61K31/138 |
代理公司: | 永新专利商标代理有限公司 | 代理人: | 王 磊;过晓东 |
地址: | 美国加*** | 国省代码: | 美国;US |
权利要求书: | 查看更多 | 说明书: | 查看更多 |
摘要: | 本发明提供了式(1)的取代氨基缩水甘油基化合物、其制备方法和其药物组合物及其用于治疗、预防或改善社交焦虑障碍、焦虑症、甲状腺机能亢进、震颤、青光眼、高血压、冠状动脉旁路移植、慢性稳定性心绞痛、房性心律失常、偏头痛、出血性食管静脉曲张、肥厚性主动脉瓣下狭窄、心力衰竭、心肌梗死后、近期心肌梗死后出现的左心室功能下降和/或通过β肾上腺素能受体调节剂改善的任何病症的一种或多种症状的方法。 | ||
搜索关键词: | 氘化 氨基 缩水 甘油 化合物 | ||
【主权项】:
1.下式1的化合物
或其单一对映体、其(+)-对映体和其(-)-对映体的混合物、约90重量%或更多的其(-)-对映体与约10重量%或更少的其(+)-对映体的混合物、约90重量%或更多的其(+)-对映体与约10重量%或更少的其(-)-对映体的混合物、其单一非对映体或其非对映体的混合物;或其药学上可接受的盐、其溶剂化物或其前药:其中:R3独立地选自由氢、氘和
组成的组;R4和R5各自独立地为氢或氘,或R4和R5连接在一起以形成
从而产生萘环体系;且R1、R2、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30独立地为氢或氘;条件为在所述式1的化合物中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个独立地为氘;条件为,当R4和R5连接在一起以形成
时:1)如果R1和R3为氘,则R2、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且2)如果R3为氘,则R1、R2、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且3)如果R1、R2、R3、R27、R28、R29和R30为氘,则R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25和R26中至少一个为氘;且4)如果R16为氘,则R1、R2、R3、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且5)如果R13、R14、R15、R17、R18和R19为氘,则R1、R2、R3、R6、R7、R8、R9、R10、R11、R12、R16、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且6)如果R13、R14、R15、R16、R17、R18和R19为氘,则R1、R2、R3、R6、R7、R8、R9、R10、R11、R12、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且7)如果R10和R11为氘,则R1、R2、R3、R6、R7、R8、R9、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且8)如果R6和R7为氘,则R1、R2、R3、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且9)如果R6、R7、R8、R10和R11为氘,则R1、R2、R3、R9、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;条件为,当R3为
时:1)如果R13、R14、R15、R17、R18和R19为氘,则R1、R2、R4、R5、R6、R7、R8、R9、R10、R11、R12、R16、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且2)如果R6和R7为氘,则R1、R2、R4、R5、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且3)如果R1和R5为氘,则R2、R4、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且条件为,当R3为氢时:1)如果R8为氘,则R1、R2、R4、R5、R6、R7、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘;且2)如果R10和R11为氘,则R1、R2、R4、R5、R6、R7、R8、R9、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22、R23、R24、R25、R26、R27、R28、R29和R30中至少一个为氘。
下载完整专利技术内容需要扣除积分,VIP会员可以免费下载。
该专利技术资料仅供研究查看技术是否侵权等信息,商用须获得专利权人授权。该专利全部权利属于奥斯拜客斯制药有限公司,未经奥斯拜客斯制药有限公司许可,擅自商用是侵权行为。如果您想购买此专利、获得商业授权和技术合作,请联系【客服】
本文链接:http://www.vipzhuanli.com/patent/200780028058.5/,转载请声明来源钻瓜专利网。
- 同类专利
- 专利分类
C07 有机化学
C07C 无环或碳环化合物
C07C217-00 连接在同一个碳架上的含氨基和醚化的羟基的化合物
C07C217-02 .醚化的羟基和氨基连接在同一个碳架的非环碳原子上
C07C217-52 .醚化的羟基或氨基连接在同一个碳架的除六元芳环以外的其他环的碳原子上
C07C217-54 .醚化的羟基连接在至少1个六元芳环的碳原子上和氨基连接在非环碳原子上或连接在除同一个碳架的六元芳环以外的其他环的碳原子上
C07C217-76 .带有连接在六元芳环碳原子上的氨基和连接在非环碳原子或同一碳架的除六元芳环以外的其他环碳原子上的醚化羟基
C07C217-78 .带有连接在同一碳架的六元芳环的碳原子上的氨基和醚化羟基
C07C 无环或碳环化合物
C07C217-00 连接在同一个碳架上的含氨基和醚化的羟基的化合物
C07C217-02 .醚化的羟基和氨基连接在同一个碳架的非环碳原子上
C07C217-52 .醚化的羟基或氨基连接在同一个碳架的除六元芳环以外的其他环的碳原子上
C07C217-54 .醚化的羟基连接在至少1个六元芳环的碳原子上和氨基连接在非环碳原子上或连接在除同一个碳架的六元芳环以外的其他环的碳原子上
C07C217-76 .带有连接在六元芳环碳原子上的氨基和连接在非环碳原子或同一碳架的除六元芳环以外的其他环碳原子上的醚化羟基
C07C217-78 .带有连接在同一碳架的六元芳环的碳原子上的氨基和醚化羟基